97 related articles for article (PubMed ID: 16094629)
1. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone.
Yao CJ; Lai GM; Chan CF; Cheng AL; Yang YY; Chuang SE
Int J Cancer; 2006 Feb; 118(3):773-9. PubMed ID: 16094629
[TBL] [Abstract][Full Text] [Related]
2. A Synergistic Anti-Cancer Effect of Troglitazone and Lovastatin in a Human Anaplastic Thyroid Cancer Cell Line and in a Mouse Xenograft Model.
Zhong WB; Tsai YC; Chin LH; Tseng JH; Tang LW; Horng S; Fan YC; Hsu SP
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29932104
[TBL] [Abstract][Full Text] [Related]
3. The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells.
Vitale G; Zappavigna S; Marra M; Dicitore A; Meschini S; Condello M; Arancia G; Castiglioni S; Maroni P; Bendinelli P; Piccoletti R; van Koetsveld PM; Cavagnini F; Budillon A; Abbruzzese A; Hofland LJ; Caraglia M
Biotechnol Adv; 2012; 30(1):169-84. PubMed ID: 21871555
[TBL] [Abstract][Full Text] [Related]
4. The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells.
Yan KH; Yao CJ; Chang HY; Lai GM; Cheng AL; Chuang SE
Mol Carcinog; 2010 Mar; 49(3):235-46. PubMed ID: 19908241
[TBL] [Abstract][Full Text] [Related]
5. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.
Rao S; Lowe M; Herliczek TW; Keyomarsi K
Oncogene; 1998 Nov; 17(18):2393-402. PubMed ID: 9811471
[TBL] [Abstract][Full Text] [Related]
6. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines.
Koga H; Sakisaka S; Harada M; Takagi T; Hanada S; Taniguchi E; Kawaguchi T; Sasatomi K; Kimura R; Hashimoto O; Ueno T; Yano H; Kojiro M; Sata M
Hepatology; 2001 May; 33(5):1087-97. PubMed ID: 11343236
[TBL] [Abstract][Full Text] [Related]
7. Combined treatment with troglitazone and lovastatin inhibited epidermal growth factor-induced migration through the downregulation of cysteine-rich protein 61 in human anaplastic thyroid cancer cells.
Chin LH; Hsu SP; Zhong WB; Liang YC
PLoS One; 2015; 10(3):e0118674. PubMed ID: 25742642
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J
Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936
[TBL] [Abstract][Full Text] [Related]
9. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.
Kubota T; Koshizuka K; Williamson EA; Asou H; Said JW; Holden S; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3344-52. PubMed ID: 9699665
[TBL] [Abstract][Full Text] [Related]
10. Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells.
Motomura W; Takahashi N; Nagamine M; Sawamukai M; Tanno S; Kohgo Y; Okumura T
Int J Cancer; 2004 Jan; 108(1):41-6. PubMed ID: 14618613
[TBL] [Abstract][Full Text] [Related]
11. E2F activity is biphasically regulated by androgens in LNCaP cells.
Hofman K; Swinnen JV; Verhoeven G; Heyns W
Biochem Biophys Res Commun; 2001 Apr; 283(1):97-101. PubMed ID: 11322773
[TBL] [Abstract][Full Text] [Related]
12. Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines.
Shen YC; Hsu C; Chen JY; Cheng AL
Br J Cancer; 2004 Oct; 91(8):1561-5. PubMed ID: 15467764
[TBL] [Abstract][Full Text] [Related]
13. Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells.
Koga H; Harada M; Ohtsubo M; Shishido S; Kumemura H; Hanada S; Taniguchi E; Yamashita K; Kumashiro R; Ueno T; Sata M
Hepatology; 2003 May; 37(5):1086-96. PubMed ID: 12717389
[TBL] [Abstract][Full Text] [Related]
14. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells.
Motomura W; Okumura T; Takahashi N; Obara T; Kohgo Y
Cancer Res; 2000 Oct; 60(19):5558-64. PubMed ID: 11034103
[TBL] [Abstract][Full Text] [Related]
15. Sesamin synergistically potentiates the anticancer effects of γ-tocotrienol in mammary cancer cell lines.
Akl MR; Ayoub NM; Abuasal BS; Kaddoumi A; Sylvester PW
Fitoterapia; 2013 Jan; 84():347-59. PubMed ID: 23266736
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment of gamma-tocotrienol with statins induce mammary tumor cell cycle arrest in G1.
Wali VB; Bachawal SV; Sylvester PW
Exp Biol Med (Maywood); 2009 Jun; 234(6):639-50. PubMed ID: 19359655
[TBL] [Abstract][Full Text] [Related]
17. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators.
Yin F; Wakino S; Liu Z; Kim S; Hsueh WA; Collins AR; Van Herle AJ; Law RE
Biochem Biophys Res Commun; 2001 Sep; 286(5):916-22. PubMed ID: 11527386
[TBL] [Abstract][Full Text] [Related]
18. Lovastatin-induced apoptosis is mediated by activating transcription factor 3 and enhanced in combination with salubrinal.
Niknejad N; Gorn-Hondermann I; Ma L; Zahr S; Johnson-Obeseki S; Corsten M; Dimitroulakos J
Int J Cancer; 2014 Jan; 134(2):268-79. PubMed ID: 23824972
[TBL] [Abstract][Full Text] [Related]
19. Involvement of MEK-ERK signaling pathway in the inhibition of cell growth by troglitazone in human pancreatic cancer cells.
Motomura W; Tanno S; Takahashi N; Nagamine M; Fukuda M; Kohgo Y; Okumura T
Biochem Biophys Res Commun; 2005 Jun; 332(1):89-94. PubMed ID: 15896303
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines.
Yoshizawa K; Cioca DP; Kawa S; Tanaka E; Kiyosawa K
Cancer; 2002 Nov; 95(10):2243-51. PubMed ID: 12412180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
